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Abstract: Posaconazole (POS) is a novel antifungal agent, which has been repurposed as an anti-tumor drug for its 
potential inhibition of Hedgehog signaling pathway. Hedgehog pathway is reported to be abnormally activated in 
embryonal rhabdomyosarcoma (ERMS), this study aimed to reveal whether POS could inhibit Hedgehog signaling 
pathway in ERMS. Following POS treatment, XTT viability assay was used to determine the cell proliferation of ERMS 
cell lines. Protein changes related to Hedgehog signaling, cell cycle and autophagy were detected by Western blot. 
The cell cycle distribution was analyzed by flow cytometry. Moreover, a subcutaneous tumor mouse model of ERMS 
was established to assess the anti-tumor effect of POS. POS was found to inhibit tumor progression by inducing 
G0/G1 arrest and autophagy of RD, RMS-YM, and KYM-1 cells dose-dependently. Western blot demonstrated that 
POS downregulated the expressions of SMO, Gli1, c-Myc, CDK4, and CDK6, while upregulated the expressions 
of autophagy-related proteins. Immunofluorescence microscopy revealed a significant increase of LC3B puncta in 
POS-treated ERMS cells. Furthermore, POS treatment led to a significant inhibition of tumor growth in mice bearing 
ERMS. Our findings could provide a theoretical basis and have important clinical implications in developing POS as 
a promising agent against ERMS by targeting Hedgehog pathway.
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Introduction
Rhabdomyosarcoma (RMS) is the most com-
mon soft tissue sarcoma in children and is 
regarded as one of the main pediatric solid 
tumors. RMS can be classified into two main 
subtypes, embryonal RMS (ERMS) and alveolar 
RMS (ARMS). The current standard treatment 
of ERMS is mainly multidisciplinary with a com-
bination of surgical tumor excision, systemic 
chemotherapy comprised of vincristine, actino-
mycin D, and cyclophosphamide or ifosfamide 
and radiation therapy. Although some localized 
ERMS lesions can be cured, the prognosis of 
metastatic or recurrent ERMS is not ideal 
[1, 2]. Especially for the treatment of urinary 
ERMS such as bladder and prostate ERMS, it 
remains a challenge to significantly improve 
survival through the main mode of extensive 
surgical resection after chemotherapy [3]. And 
the multidisciplinary treatment may impair the 
bladder function and erectile function [3]. 
Therefore, it is still necessary to explore new 
ERMS therapies with meliorative oncological 
and functional outcomes.
Hedgehog signaling plays an essential role in 
regulating a series of embryonic development 
processes, such as cell growth, differentiation 
and organogenesis [4-6]. Related studies have 
demonstrated that the aberrant activation of 
Hedgehog signaling pathway is mediated by 
the transmembrane proteins Patched (PTCH) 
and Smoothened (SMO) in multiple types of 
cancers [7]. The binding of Hedgehog signal to 
PTCH relieves SMO inhibition, which subse-
quently activates the transcription factors of 
glioma-associated oncogene (Gli) family (Gli1, 
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ction of Research Bioresources Cell Bank 
(Ibaraki, Japan). The cell line (RMS-YM) derived 
from ERMS was obtained from Riken Cell 
Bank (Tsukuba, Japan). These three cell lines 
were cultured in RPMI-1640 medium (Gibco, 
Invitrogen, USA) supplemented with 10% fetal 
bovine serum (FBS, Gibco, USA) and 1% peni- 
cillin/streptomycin (Gibco, USA). The cells were 
maintained in a humidified incubator at 37°C 
with 5% CO2.
Reagents and antibodies
POS was purchased from MedChemExpress 
(MCE, New Jersey, USA), and its molecular 
structure is shown in Figure 1D. POS was dis-
solved in dimethyl sulfoxide (DMSO) to a for- 
mation of 10 mM stock solution for the in vitro 
experiments. The primary antibodies for West- 
ern Blot analysis were as follows: β-actin (CST, 
#4970, 1:1000), Gli1 (Santa Cruz Biotechno- 
logy, sc-515751, 1:800), SMO (Proteintech, 
20787-1-AP, 1:1000), p21Waf1/Cip1 (CST, #2947, 
1:1000), c-Myc (CST, #18583, 1:1000), CDK4 
(CST, #2906, 1:1000), CDK6 (CST, #3136, 
1:1000), Atg5 (CST, #9980, 1:1000), Beclin-1 
(CST, #3495, 1:1000), LC3B (CST, #3868, 
1:1000). The secondary antibodies were anti-
rabbit IgG, HRP-linked Antibody (1:2000, CST, 
#7074), and anti-mouse IgG, HRP-linked Anti- 
body (CST, #7076, 1:2000). SMO antibody 
(Proteintech, 20787-1-AP, 1:200) was used for 
the immunohistochemistry, LC3B antibody 
(CST, #3868, 1:500) was used for immuno- 
fluorescence staining.
XTT cell viability assay
Cell viability was detected by the XTT assay 
(Roche Diagnostics, USA). ERMS cells (1,000-
3,000/well) were seeded in a 96-well plate 
and allowed to attach overnight. Then the cells 
were incubated with POS at concentrations 
ranging from 0 to 100 μM for 24, 48 and 72 h. 
At the indicated time point, XTT reagent was 
added and then incubated for 4 to 24 h. The 
optical density (OD) levels were determined 
using a microplate reader (model 680; Bio-Rad 
Laboratories, Inc., USA).
Western blot analysis
ERMS cells were seeded in 6-well plates and 
treated with POS (0, 10 and 25 μM) for 24 h 
according to the results of XTT assay. Then the 
treated cells were lysed in ice-cold lysis buffer 
Gli2 and Gli3). As the nuclear executor, the Gli 
transcription factors are responsible for regu-
lating the expressions of the downstream tar-
get genes [8, 9]. Inhibition of Hedgehog path-
way could reduce cell proliferation and induce 
autophagy in non-Hodgkin lymphoma, chronic 
myeloid leukemia, and colon cancer [10-12]. 
The development and progression of ERMS are 
closely related to the consistent activation of 
Hedgehog signaling pathway and increasing 
evidence indicates that novel strategies target-
ing the Hedgehog pathway will be promising 
therapeutics for patients with ERMS [7, 13].
Posaconazole (POS), a second-generation tri-
azole antifungal drug, is a potent inhibitor of 
the Hedgehog signaling pathway, which has 
been redefined as an anti-tumor compound 
recently. Most studies have focused on the 
effect of POS on fungi, ignoring the role of POS 
in other diseases such as tumors. POS inhibits 
the Hedgehog signaling pathway by targeting 
the class Frizzled (Class F) G protein-coupled 
receptor SMO, which is a key transmembrane 
protein of the Hedgehog signaling. Notably, 
POS has been shown to be effective in several 
types of tumors through the Hedgehog signal-
ing pathway [14], such as glioblastoma [15], 
acute myeloid leukemia [16], and basal cell 
carcinoma [17]. However, the effect of POS on 
ERMS remains to be determined.
This study was designed to investigate the 
potential effect of POS on Hedgehog signaling 
pathway in ERMS. There is currently no com-
mercial cell line derived from bladder ERMS, 
so we tested the effect of POS on Hedgehog 
signaling using ERMS cell lines including RD, 
RMS-YM, and KYM-1. Firstly, we identified the 
abnormal expression of SMO in human blad- 
der ERMS samples and ERMS cell lines. Then 
POS was demonstrated to decrease cell via- 
bility, trigger cell cycle arrest, and induce cell 
autophagy in ERMS cell lines. Furthermore, 
the in vivo experiment confirmed that POS 
inhibited tumor growth in a xenograft murine 
model of ERMS. These findings may provide a 
theoretical basis for POS as a novel anti-tumor 
agent against ERMS, or even bladder ERMS.
Materials and methods
Cell lines and cell culture
The cell lines (RD and KYM-1) derived from 
ERMS, were purchased from Japanese Colle- 
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which contained protease and phosphatase 
inhibitor cocktail (#78501, Thermo Scientific, 
USA). Protein samples were separated by 10% 
or 12% SDS/polyacrylamide gel (Bio-Rad, 
Hercules, CA, USA) electrophoresis and then 
transferred to polyvinylidene difluoride mem-
brane. The membrane was incubated with pri-
mary antibodies at 4°C overnight. The next 
day, the membrane was washed for 3-5 times 
and then incubated with the corresponding 
secondary antibody at room temperature for 1 
h. Finally, the immunoblots were visualized by 
the enhanced chemiluminescence (ECL) kit 
(Amersham Pharmacia Biotech, USA) and 
ChemiDoc Imaging System (Bio-Rad, USA). β- 
actin were regarded as the internal reference. 
The expression level of proteins was quantified 
by ImageJ software.
Figure 1. SMO expressed in bladder ERMS and POS inhibits Hedgehog signaling pathway in ERMS cells. A. Rep-
resentative images of immunohistochemical staining for SMO in the tumor sections from human bladder ERMS 
tissues. Scale bar =20 μm. B. The SMO positive rate of bladder ERMS tissues (ten cases) was significantly higher 
than that of adjacent non-tumor tissues (ten cases). Data are presented as mean ± SD. N=10, ***P<0.001 vs. the 
adjacent group. C. SMO expressions in RD, RMS-YM, and KYM-1 cell lines. D. The chemical structure of POS. E. POS 
treatment for 24 h reduced the levels of SMO and Gli1 in ERMS cell lines. β-actin expression was regarded as an 
internal reference.
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Cell cycle distribution analysis
According to the instructions for the Cell Cycle 
Analysis kit (BD Biosciences, San Jose, CA, 
USA), ERMS cells (3×105/well) were seeded in 
a 6-well plate overnight, and then incubated 
with the fresh media with 10 µM POS. Follow- 
ing 24 h treatment, the cells were harvested 
and then fixed with pre-cooled 70% ethanol. 
The next day, the fixed cells were washed 
twice in order to remove the residual ethanol 
(the first wash with PBS and the second one 
with the stain buffer (#554656, BD Biosci- 
ences). Subsequently, the cells were resus-
pended with PI/RNase staining buffer (#550- 
825, BD Biosciences). The cells could be fur-
ther incubated for 15 min and then analy- 
zed by the MACSQuant Analyzer 10 (Miltenyi 
Biotec, Germany).
Transmission electron microscopy (TEM) ob-
servation
ERMS cells were seeded in 6-well plates at 
3×105 per well overnight, followed by 24 h in- 
cubation with the fresh media containing 25 
µM POS. The harvested cells were fixed in 2% 
glutaraldehyde at 4°C overnight. Subsequent- 
ly, they were rinsed with PBS twice and then 
fixed with 1% osmium tetroxide for 3 h. The 
cell samples were next dehydrated using an 
ascending acetone series, followed by embed-
ding and gradient polymerization. Next, the 
ultrathin sections were prepared and double-
stained with uranyl acetate and lead citrate. 
The autophagic structures in POS-treated 
ERMS cells were observed under H-7650 
transmission electron microscope (Hitachi Co., 
Japan).
Immunofluorescence staining
ERMS cells were plated on a glass-bottom dish 
and cultured overnight. After incubation with 
25 µM POS for 24 h, the cells were fixed with 
4% formaldehyde at room temperature for 15 
min, and then rinsed with PBS. Subsequently, 
they were incubated with LC3B antibody in a 
humidified chamber at 4°C overnight. The next 
day, after washing with PBS three times for 5 
min each, the cells were treated with the fluo-
rescent-labeled secondary antibody for 1 h at 
room temperature in dark. Finally, the nuclei 
were counterstained with DAPI, followed by 
examination and photography through a fluo-
rescence microscope. Image J software was 
applied to quantify the number of LC3B puncta 
per cell from five random fields of view.
ERMS subcutaneous implantation in SCID 
mice
RD cells (1×107) were suspended in 50 µL 
Hank’s balanced salt solution and 50 µL Ma- 
trigel (#356234, BD Biosciences, USA), and 
then subcutaneously inoculated into the left 
rear flank of SCID mice. Once the tumor volu- 
me reached about 100 mm3, the mice were 
randomized into two groups (six mice per 
group), and orally received vehicle or POS (70 
mg/kg) every day for 2 weeks before sacri- 
fice. The tumor volume was measured with a 
caliper and then recorded twice every week. 
In the final stage of animal experiment, blood 
samples were collected for the serum analysis 
of liver function indicators such as glutamic-
oxaloacetic transaminase (GOT) and glutamic-
pyruvic transaminase (GPT). The tumor tissues 
were surgically resected and used for subse-
quent immunohistochemistry, and hematoxy-
lin-eosin (HE) staining. All procedures of this 
animal experiment were approved by the Oka- 
yama University Ethics Committee.
Human bladder ERMS specimens
The tissue samples were collected after sur-
gery, and pathologically diagnosed as bladder 
ERMS at Zhujiang Hospital. The specimens 
(ten cases) were matched with adjacent non-
tumor tissues (ten cases) for comparison. After 
the tissues were cut into 4 μm sections, they 
were then fixed in formalin, and embedded in 
paraffin to assess the expression of SMO. The 
study protocol was approved by the Medical 
Ethics Committee of Zhujiang Hospital. Infor- 
med consents were signed, and obtained from 
all the subjects.
Immunohistochemistry staining
The tumor tissue was removed, fixed in the 
formalin, and then embedded in the paraffin. 
After deparaffinization by xylene, the sections 
were rehydrated in a graded series of ethanol. 
Subsequently, the antigen retrieval was con-
ducted by autoclave treatment in 10 mM pH 
6.0 sodium citrate buffer at 120°C for 20 min. 
The 3% Hydrogen Peroxide (H2O2) was used to 
block the endogenous peroxidase activity for 
10 min. To prevent non-specific staining, the 
sections were placed in 10% normal goat 
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serum solution for 40 min. Tissue sections 
were then incubated with SMO antibody (Pro- 
teintech, #20787-1-AP, 1:200), at 4°C over-
night. After washed by PBS, the sections were 
then incubated with the secondary antibody at 
room temperature for 30 min. The DAB sub-
strate kits (425312F, Nichirei Bioscience Inc.) 
were used for staining and the sections were 
then lightly counterstained by hematoxylin. 
Finally, the sections were observed and photo-
graphed under a microscope. The SMO posi- 
tive rate was calculated from ten random fields 
of view.
Statistical analysis
All experiments were repeated independently 
for at least three times and all the data were 
presented as mean ± standard deviation (SD). 
The statistical data were processed by Graph- 
Pad Prism 8 software. Between-group varianc-
es were assessed with one-way or two-way 
analysis of variance, and the P value <0.05 
was regarded as statistical significance.
Results
Overexpression of SMO in bladder ERMS 
specimens
The previous study has demonstrated the 
expression of SMO in RMS specimens [18]. To 
date, there have been no studies reporting 
SMO expression in bladder ERMS. In this 
study, SMO expression in bladder ERMS was 
evaluated by immunohistochemistry staining. 
As shown in Figure 1A, SMO was significantly 
overexpressed in bladder ERMS samples com-
pared to paired adjacent non-tumor tissues. 
The SMO positive rate of bladder ERMS tis- 
sues was significantly higher than that of adja-
cent non-tumor tissues (Figure 1B).
POS inhibits Hedgehog signaling pathway
SMO expression was firstly identified in RD, 
RMS-YM, and KYM-1 cell lines (Figure 1C). 
SMO and Gli1 were then selected as the 
representatives to confirm the inhibitory effect 
of POS on Hedgehog signaling pathway. As 
shown in Figure 1E, POS downregulated the 
expressions of SMO and Gli1 in a concentra-
tion-dependent manner.
POS suppresses the cell viability of ERMS cell 
lines
XTT assay was conducted to assess the eff- 
ect of POS on the cell viability of ERMS cell 
lines. RD, RMS-YM and KYM-1 cells were treat-
ed with different concentrations of POS (0, 10, 
25, 50, and 100 μM) for 24, 48, and 72 h. As 
shown in Figure 2A-C, POS inhibited the cell 
viability of three ERMS cell lines in a time- and 
concentration-dependent manner. The half-
maximal inhibitory concentration (IC50) of POS 
at 24 h was 36.51 μM and 62.62 μM for RD 
and RMS-YM cells, respectively. And RD cells 
were more sensitive to POS than RMS-YM and 
KYM-1 cells.
POS triggers G0/G1 cell cycle arrest in ERMS 
cell lines
After treated with 10 μM POS for 24 h, a higher 
percentage of RD, RMS-YM and KYM-1 cells 
Figure 2. POS suppresses cell viability in human 
ERMS cells. XTT assay was performed to assess the 
effect of POS on the cell viability of RMS cell lines. 
POS inhibited the cell viability of (A) RD, (B) RMS-YM, 
and (C) KYM-1 in a time- and concentration-depen-
dent manner. Data are presented as mean ± SD. 
N=6, *P<0.05 vs. the control group.
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stayed at G0/G1 phase was found in the treat-
ment group compared with the control group 
(Figure 3A, 3B). Subsequently, in order to 
elucidate the molecular mechanism of POS-
induced cell cycle arrest, we further measured 
the cell cycle related proteins through western 
blot after ERMS cells were treated with POS 
(10 and 25 μM). POS was found to effectively 
upregulate the expression of p21Waf1/Cip1, while 
POS downregulated c-Myc, CDK4, and CDK6 
in a concentration-dependent manner (Figure 
3C). The results above indicated that POS 
induces G0/G1 phase arrest in RD, RMS-YM, 
and KYM-1 cells.
POS induces cell autophagy in ERMS cell lines
Several studies have reported that the inhibi-
tion of Hedgehog signaling pathway is closely 
related to the occurrence of autophagy [19- 
Figure 3. POS triggers G0/G1 cell cycle arrest in RD, RMS-YM, and KYM-1 cells. A. RD, RMS-YM, and KYM-1 cells 
were treated with 10 μM POS for 24 h, and then stained with PI/RNase. Flow cytometry was performed to analyze 
the cell cycle distribution. B. The percentages of RD, RMS-YM, KYM-E cells in G0/G1, S and G2/M phases are calcu-
lated based on the flow cytometric analysis. Data are presented as mean ± SD. N=3, *P<0.05 vs. the control group. 
C. RD, RMS-YM, and KYM-1 cells were treated with POS (0 μM, 10 μM and 25 μM) for 24 h. Western blot analysis 
indicated that POS upregulated the expression of p21Waf1/Cip1 while decreased the levels of c-Myc, CDK4, and CDK6. 
β-actin expression was regarded as an internal reference.
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21]. Hence, we tried to determine whether POS 
could induce autophagy in ERMS cell lines 
under TEM. For all three ERMS cell lines, sig- 
nificant autophagosome formation was obser- 
ved in the treatment group (Figure 4A). After- 
wards, immunofluorescence staining for LC3B 
was performed in RD and RMS-YM cells, and 
the results indicated that the number of LC3B 
puncta per cell significantly increased with the 
treatment of 25 μM POS (Figure 4B, 4C). To 
further prove our assumption, western blot 
analysis was conducted to detect the expres-
sions of autophagy related proteins. POS ele-
vated the expressions of Atg5, Beclin-1, and 
LC3-II in a dose-dependent manner (Figure 
4D).
Anti-tumor potential of POS in vivo
The ERMS xenograft mouse model of RD cells 
was established to assess the therapeutic 
effect of POS. Tumor-bearing mice were orally 
administered with vehicle or POS (70 mg/kg) 
every day for 2 weeks. The representative 
change of tumor size (Figure 5A) in mice treat-
ed with POS was significantly lower than that 
in the control group. The average tumor weight 
was (0.598±0.241) g in the control group, and 
(0.150±0.051) g in treatment group (Figure 
5B). Following two-week treatment, the tumor 
volume grew slowly in POS group when com-
pared to the control group (Figure 5C). HE 
staining was conducted to examine the histo-
pathological morphological changes. The tu- 
mor cells in POS group were characterized by 
disappeared nuclei and tumor necrosis, while 
those in vehicle group showed deeply stain- 
ed, large and abnormal nuclei in intact cells 
(Figure 5D). Through HE staining performance 
in Figure 5E, POS could cause a certain extent 
of liver damage compared to vehicle group. For 
the analysis of liver function, no statistical dif-
ference was found in GOT (Figure 5F) and GPT 
(Figure 5G) after POS treatment, but the mean 
value of GPT in POS group was higher than that 
in vehicle group.
Discussion
As second-generation triazole antifungal drug, 
POS has exhibited certain anti-tumor proper-
ties and repurposed as an anti-tumor com-
pound in recent years [17]. Our results demon-
strated that POS suppressed cell viability, in- 
duced G0/G1 cell cycle arrest and autophagy 
in ERMS cells through inhibition of Hedgehog 
signaling pathway. Through the downregu- 
lation of SMO and Gli1 detected by western 
blot, POS was found to effectively inhibit the 
Hedgehog signaling pathway. XTT assay indi-
cated that POS inhibited the proliferation of 
human ERMS cell lines including RD (ERMS 
from pelvis), RMS-YM (ERMS from urachus), 
and KYM-1 (ERMS from neck), in a time- and 
concentration-dependent manner. For in vitro 
experiments, we selected the concentrations 
(10, 25 μM) below IC50 according to cell via- 
bility assay, pre-experiment basis, and the 
related literatures [13, 17] of conventional 
Hedgehog inhibitors.
Arrest of tumor cell cycle progression has been 
regarded as promising in tumor treatment [22]. 
Regulation of embryonic development is the 
main role of Hedgehog signaling pathway and 
regulation of proliferation is the most basic 
function of Hedgehog signaling pathway [23]. 
Previous studies have shown that Hedgehog 
signaling pathway could alter the distribution of 
tumor cell cycle [12, 24]. In this study, flow 
cytometry demonstrated that the proportion of 
ERMS cells at G0/G1 stage increased signifi-
cantly after POS treatment. More tumor cells 
were arrested at G0/G1 phase would result in 
impaired DNA replication, thus reducing the 
proliferation ability of ERMS cells. Western blot 
revealed that the expression of p21Waf1/Cip1 was 
significantly upregulated, while the expressions 
of c-Myc, CDK4, and CDK6 were downregulat- 
ed following POS treatment. p21 is a classic 
p53-regulated cell cycle inhibitor and c-Myc 
plays a crucial role in sustaining the prolifera-
tion of human tumor cells, which promotes the 
cell cycle progression from G1 to S stage. 
Cyclin-dependent kinases 4/6 (CDK4/CDK6) 
are the downstream cell cycle regulators of 
p21, which can promote the transition from G0 
to G1 phase [25]. Our data suggest that POS 
treatment could prevent the transition from G0 
into G1 phase by downregulating the expres-
sions of CDK4 and CDK6, which were regulat- 
ed by p53/c-Myc/p21 signals.
Autophagy involves the delicately regulated 
catabolic digestion of damaged cell organelles 
and proteins mediated by lysosomes. Although 
the role of autophagy in tumors has not been 
definitely determined, accumulating evidence 
indicates that the induction of autophagy and 
inhibition of autophagosome degradation can 
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Figure 4. POS induces cellular autophagy in ERMS cells. A. RD, RMS-YM, and KYM-1 cells were treated with 25 μM 
POS for 24 h. Representative images of autophagosome formation were observed by TEM analysis (black scale bar 
=2 μm, white scale bar =1 μm). B. The expressions of LC3B in RD and RMS-YM cells following 25 μM POS treatment 
were detected by immunofluorescence staining (green) whereas the nuclei were stained with DAPI (blue). (Red 
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inhibit tumor progression. Several novel drugs 
have been identified to induce autophagic cell 
death (ACD), which are regarded as promising 
anti-tumor therapy [26]. The process of auto- 
phagy is mediated by a series of autophagy-
related genes (ATG). The formation of double-
membrane vesicles, termed as autophago-
somes, marks the beginning of autophagy. The 
microtubule-associated protein light chain 3 
(LC3), especially the lipidated LC3-II, plays a 
key role in the initiation of autophagy process. 
Beclin-1 (Atg6), a tumor suppressor gene, is 
generally downregulated in many different can-
cers, and promotes the formation or transpor-
tation of autophagosomes. The TEM images 
exhibited significant autophagosome forma- 
tion of double-membrane autophagosomes in 
all three cell lines after POS treatment. The 
number of autophagic vacuoles (autophago-
somes plus autolysosomes) in POS treatment 
group was visibly larger than that in control 
group. Western blot analysis revealed that POS 
scale bar =20 μm). C. The number of LC3B puncta per cell from five random fields of view was quantified in RD and 
RMS-YM cells after 25 μM POS treatment. (N=5, **P<0.01). D. Western blot analysis of Atg5, Beclin-1, LC3-I, and 
LC3-II in RD, RMS-YM, and KYM-1 cells after POS treatment for 24 h. β-actin expression was regarded as an internal 
reference.
Figure 5. POS inhibits RD cell growth in vivo. A. Images of the resected ERMS tumors from mice were photographed 
after two-week treatment. B. The average weight of tumors in POS (70 mg/kg) group was significantly lower than 
that in the control group. Data are presented as mean ± SD. N=5, **P<0.01 vs. the control group. C. The tumor vol-
ume was measured twice every week. Data are presented as mean ± SD. N=5, ***P<0.001 vs. the control group. D. 
HE staining of ERMS tissues indicated that the disappeared nuclei and tumor necrosis were identified in POS group, 
while the deeply stained, large and abnormal nuclei in intact cells were found in the control group. Scale bar =50 
μm. E. HE staining of mice liver showed some liver impairment after POS treatment compared to the control group. 
Scale bar =50 μm. F, G. The analysis of liver function revealed no statistical difference in GOT and GPT between POS 
treatment group and control group, but mean GPT of the POS group was higher than that of control group. Data are 
presented as mean ± SD. N=4, ns: not significant vs. the control group.
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treatment upregulated the expressions of 
Atg5, Beclin-1, and LC3-II. The upregulation of 
these proteins verified the occurrence of auto- 
phagy in ERMS cells following POS treatment. 
Subsequently, immunofluorescence staining 
was performed to confirm the number of LC3B 
puncta per cell in RD and RMS-YM cells, which 
distinctly increased after POS treatment.
Hedgehog signaling pathway has significant 
implications in the regulation of cell cycle and 
autophagy. Gli proteins may serve as both 
transcriptional activators and repressors in 
the Hedgehog signaling pathway. In the ab- 
sence of Hedgehog Signaling, the C-terminally 
truncated Gil2/3 function as the transcription- 
al repressors while Gli1 is generally considered 
to be a transcriptional activator [27]. Gli1 is 
regarded as a prooncogenic role in a series of 
cancers and plays a certain role in the cancer 
stem cell maintenance. When the Hedgehog 
signaling pathway is activated, Gli proteins 
cannot be phosphorylated and degraded so 
that they remain the Gli-activated form (GliA). 
While the active Gli2/3 would promote the 
expression and transcription of Gli1, thus pro-
moting tumorigenesis [28]. Gli1 has been ap- 
plied as a biomarker to determine the activa-
tion of Hedgehog signaling pathway [27, 28]. In 
addition, previous studies have revealed that 
Gli1 can regulate the cell cycle progression 
[29] and the process of cell autophagy [30]. 
Therefore, we chose to analyze the expression 
level of Gli1 to assess the inhibitory effect 
of POS on Hedgehog signaling pathway. The 
previous study has indicated that Hedgehog 
signaling negatively regulates the expression 
of p53-independent p21Waf1/Cip1 through Gli1, 
thereby affecting the cell cycle transition from 
G1 to S phase [24]. Cellular autophagy can be 
impaired by the overexpressions of PTCH or 
SMO. The transmembrane protein SMO recep-
tor plays an essential role in Hedgehog path-
way-regulated autophagy as SMO protein mod-
ulates the synthesis of autophagosomes [31]. 
For the above reasons, we detected the key 
proteins of Hedgehog signaling pathway, in- 
cluding SMO and Gli1, which not only proved 
the inhibitory effect of POS on Hedgehog sig-
naling pathway, but also further confirmed the 
upstream pathway components in the regula-
tion of cell cycle arrest and cellular autophagy 
(Figure 6). The tumors grew more slowly in the 
treatment group than in the control group, re- 
vealing that POS (70 mg/kg) had an effective 
anti-tumor potency in ERMS xenograft mice 
model. Consistently, the tumor cells in POS 
group were characterized by disappeared 
nuclei and tumor necrosis.
Traditional inhibitors of Hedgehog signaling 
pathway may have some problems and limita-
tions when applied as anti-tumor drugs or 
anti-RMS drugs. As is shown in relevant study 
[32], the classical Hedgehog signaling pathway 
inhibitors, such as Cyclopamine, Vismodegib, 
and Sonidegib, with high concentrations, may 
lead to off-target effect on Gli1 expression in 
certain RMS cell lines, which impedes the 
research path of targeting Hedgehog signaling 
pathway for the treatment of RMS to some 
extent. Actually, the occurrence of off-target 
effect is highly correlated with the mechanism 
of action and pharmacokinetics, certain cell 
lines and drug concentrations so that the anti-
tumor effects of different inhibitors targeting 
Hedgehog signaling pathway are diversified 
[13]. In this study, we couldn’t completely 
prove whether POS treatment would cause the 
off-target effect on Gli1 expression, while no 
relevant studies have reported that POS has 
similar problems to traditional inhibitors. More- 
over, POS has been verified to inhibit Hedge- 
hog signaling pathway at distinct sites from 
other traditional Hedgehog signaling pathway 
inhibitors, revealing that the action mecha- 
nism of POS is different from traditional inhibi-
tors [17]. Our results demonstrated that Gli1 
expressions in three ERMS cell lines from dif-
ferent tissue origins were dose-dependently 
downregulated with POS treatment of 10 μM 
and 25 μM, showing the consistent experi- 
mental results in different cell lines under the 
same concentrations of POS. Therefore, we 
believe that POS would not lead to off-target 
effect on Gli1 expression at least in the used 
concentration range. Meanwhile, traditional 
SMO inhibitors have relatively severe side 
effects, while the novel SMO inhibitor POS 
possesses the advantages of few drug inter- 
actions and less damage to liver and kidney 
function, and even the potentials against drug-
resistant SMO mutants, which ensures its 
potential use as a long-term medication for 
tumor treatment [33]. In ERMS xenograft SCID 
mice model, POS therapy could cause some 
liver impairment by HE staining, and increase 
mean GPT, but there was no statistical differ-
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ence in GOT. Thus, more preclinical studies are 
required to verify the effect of POS at different 
doses on liver function. The high expression of 
SMO in bladder ERMS indicates that therapy 
targeting SMO in Hedgehog signaling pathway 
may be a promising strategy. The dynamic 
subcellular distributions of SMO in ERMS cells 
over a time course [34], more preclinical and 
clinical studies are needed to better elucidate 
the role of POS as a potential agent against 
bladder ERMS.
In summary, our findings imply that POS sup-
presses cell viability and induces G0/G1 cell 
cycle arrest and autophagy in three ERMS cell 
lines through inhibition of Hedgehog signaling 
pathway. Moreover, our proposal might also 
be applicable in bladder ERMS treatment with 
POS. Hence, POS may be a potent therapeutic 
agent to inhibit ERMS, even bladder ERMS 
through targeting SMO in Hedgehog signaling 
pathway.
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